Catheter-based renal denervation (RD) has been introduced recently as a potentially effective invasive treatment of refractory hypertension. The proportion of patients with severe hypertension suitable for RD is not clear. The aim of this study was to identify what percentage of patients has truly resistant essential hypertension and are thus potentially eligible for RD. We investigated 205 consecutive patients referred to a university hypertension center for severe hypertension within 12 months. Ambulatory 24-h blood pressure (BP) monitoring (24 h ABPM), secondary hypertension screening and compliance to treatment testing (by use of plasma drug level measurements) were performed in all patients. Fifty-seven patients (27.8%) did not have truly resistant hypertension (RH) based on clinical BP. Among the remaining 122 patients (59.5%) with RH confirmed by 24 h ABPM, 50 patients (24.4% of the original cohort) had a secondary cause of hypertension and in 27 (13.2%) non-compliance to treatment was confirmed. Thus, only 45 patients (22%) had truly resistant essential hypertension and were considered for RD. Only one-third (n=15, 7.3% of the original cohort) was, however, finally referred for RD (14 were excluded due to contraindications for RD and 16 refused the invasive treatment). In conclusion, thorough examination of severe hypertension including 24 h ABPM, secondary hypertension exclusion and drug compliance testing before considering RD reveals that majority of these patients are not suitable for RD. Specifically, compliance to treatment testing should be mandatory in order to identify eligible candidates for RD.

] 3rd Department of Medicine Centre for Hypertension General University Hospital 1st Faculty of Medicine Charles University Prague Czech Republic [2] Cardiocentre 3rd Faculty of Medicine Charles University Prague Czech Republic

3rd Department of Medicine Centre for Hypertension General University Hospital 1st Faculty of Medicine Charles University Prague Czech Republic

Cardiocentre 3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Medicine University of Mississippi Medical Center Jackson MS USA

Zobrazit více v PubMed

Hypertension. 2013 Sep;62(3):526-32 PubMed

Eur Heart J. 2013 Jul;34(28):2159-219 PubMed

J Hum Hypertens. 2014 Mar;28(3):150-6 PubMed

Hypertension. 2013 Apr;61(4):746-50 PubMed

Hypertension. 2012 Dec;60(6):1485-90 PubMed

Eur Heart J. 2013 Jul;34(28):2149-57 PubMed

J Clin Endocrinol Metab. 2008 Sep;93(9):3266-81 PubMed

Lancet. 1990 Mar 31;335(8692):765-74 PubMed

Lancet. 2002 Dec 14;360(9349):1903-13 PubMed

J Hypertens. 2012 May;30(5):837-41 PubMed

Lancet. 2010 Dec 4;376(9756):1903-9 PubMed

J Am Coll Cardiol. 2012 Dec 11;60(23):2422-4 PubMed

J Hypertens. 2013 Aug;31(8):1662-8 PubMed

Hypertension. 2011 Oct;58(4):559-65 PubMed

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Oct 15;878(28):2685-92 PubMed

J Hypertens. 2013 Dec;31(12):2455-61 PubMed

Hypertension. 2013 Aug;62(2):218-25 PubMed

Hypertension. 2011 May;57(5):911-7 PubMed

J Hypertens. 2013 Apr;31(4):766-74 PubMed

Hypertension. 2013 Sep;62(3):450-2 PubMed

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Nov 15;878(30):3167-73 PubMed

Hypertens Res. 2011 Jan;34(1):87-90 PubMed

Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence

Should All Patients with Resistant Hypertension Receive Spironolactone?

Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension